1. Home
  2. ONC vs EXE Comparison

ONC vs EXE Comparison

Compare ONC & EXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • EXE
  • Stock Information
  • Founded
  • ONC 2010
  • EXE 1989
  • Country
  • ONC Cayman Islands
  • EXE United States
  • Employees
  • ONC N/A
  • EXE N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • EXE
  • Sector
  • ONC Health Care
  • EXE
  • Exchange
  • ONC Nasdaq
  • EXE NYSE
  • Market Cap
  • ONC 26.9B
  • EXE 24.7B
  • IPO Year
  • ONC N/A
  • EXE 1993
  • Fundamental
  • Price
  • ONC $231.99
  • EXE $112.38
  • Analyst Decision
  • ONC Strong Buy
  • EXE Strong Buy
  • Analyst Count
  • ONC 7
  • EXE 17
  • Target Price
  • ONC $326.43
  • EXE $123.76
  • AVG Volume (30 Days)
  • ONC 471.3K
  • EXE 3.1M
  • Earning Date
  • ONC 05-07-2025
  • EXE 04-29-2025
  • Dividend Yield
  • ONC N/A
  • EXE 2.04%
  • EPS Growth
  • ONC N/A
  • EXE N/A
  • EPS
  • ONC N/A
  • EXE N/A
  • Revenue
  • ONC $4,175,868,000.00
  • EXE $6,568,000,000.00
  • Revenue This Year
  • ONC $860.73
  • EXE $158.16
  • Revenue Next Year
  • ONC $19.79
  • EXE $9.99
  • P/E Ratio
  • ONC N/A
  • EXE N/A
  • Revenue Growth
  • ONC 51.16
  • EXE 35.62
  • 52 Week Low
  • ONC $141.31
  • EXE $69.12
  • 52 Week High
  • ONC $287.88
  • EXE $114.03
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • EXE N/A
  • Support Level
  • ONC N/A
  • EXE N/A
  • Resistance Level
  • ONC N/A
  • EXE N/A
  • Average True Range (ATR)
  • ONC 0.00
  • EXE 0.00
  • MACD
  • ONC 0.00
  • EXE 0.00
  • Stochastic Oscillator
  • ONC 0.00
  • EXE 0.00

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About EXE EXPAND ENERGY CORPORATION

Expand Energy Corp independent natural gas producer in the United States. It is fueling a more affordable, reliable and lower-carbon future. The group focused on developing abundant natural gas, oil, and gas liquids to expand energy access.

Share on Social Networks: